ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights

15.05.2023 - Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in Alzheimer’s diseasePresented preclinical data supporting target identification and candidate differentiation across pipeline of antibody ...

Related Keywords

United States ,Boston ,Massachusetts ,Toronto ,Ontario ,Canada ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Suzanne Messere ,Johanne Kaplan ,Nasdaq ,Promis Neurosciences Inc ,Drug Development Summit ,Alzheimer Disease Program ,Toronto Stock Exchange ,Drug Administration ,American Academy Of Neurology ,International Conference On Alzheimer ,Gail Farfel ,Chief Executive Officer ,Disease Program ,Investigational New Drug ,International Conference ,Related Neurological Disorders ,American Academy ,Chief Development Officer ,Development Summit ,Collective Coordinates ,Disease Specific Epitopes ,Annual Report ,Post Effective Amendment ,Preferred Shares ,Investor Relations ,